Literature DB >> 21169615

Troponin elevation in coronary vs. non-coronary disease.

S Agewall1, E Giannitsis, T Jernberg, H Katus.   

Abstract

Acute myocardial infarction is defined as myocardial cell death due to prolonged myocardial ischaemia. Cardiac troponins (cTn) are the most sensitive and specific biochemical markers of myocardial injury and with the new high-sensitivity troponin methods very minor damages on the heart muscle can be detected. However, elevated cTn levels indicate cardiac injury, but do not define the cause of the injury. Thus, cTn elevations are common in many disease states and do not necessarily indicate the presence of a thrombotic acute coronary syndrome (ACS). In the clinical work it may be difficult to interpret dynamic changes of troponin in conditions such as stroke, pulmonary embolism, sepsis, acute perimyocarditis, Tako-tsubo, acute heart failure, and tachycardia. There are no guidelines to treat patients with elevated cTn levels and no coronary disease. The current strategy of treatment of patients with elevated troponin and non-acute coronary syndrome involves treating the underlying causes. The aim of this paper is to review data from studies of non-ACS patients with acutely elevated troponin who in clinical practice may be difficult to discriminate from ACS patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169615     DOI: 10.1093/eurheartj/ehq456

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  152 in total

1.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

Review 2.  The evolving role of cardiac troponin in the evaluation of cardiac disorders.

Authors:  Paul Anaya; David J Moliterno
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 3.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

4.  Takotsubo cardiomyopathy following ischemic stroke: a cause of troponin elevation.

Authors:  J F Scheitz; H C Mochmann; B Witzenbichler; J B Fiebach; H J Audebert; C H Nolte
Journal:  J Neurol       Date:  2011-06-18       Impact factor: 4.849

Review 5.  Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.

Authors:  Alberto Palazzuoli; Peter A McCullough; Claudio Ronco; Ranuccio Nuti
Journal:  Intern Emerg Med       Date:  2015-05-14       Impact factor: 3.397

Review 6.  High-sensitivity assays for troponin in patients with cardiac disease.

Authors:  Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg
Journal:  Nat Rev Cardiol       Date:  2017-04-06       Impact factor: 32.419

7.  Obstructive sleep apnea: no independent association to troponins.

Authors:  Trygve Sørdahl Hall; Tobias Herrscher; Petr Jarolim; Morten W Fagerland; Torstein Jensen; Jonas Hallén; Stefan Agewall; Dan Atar
Journal:  Sleep Breath       Date:  2013-09-17       Impact factor: 2.816

8.  Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children.

Authors:  Rajit K Basu; Michael Zappitelli; Lori Brunner; Yu Wang; Hector R Wong; Lakhmir S Chawla; Derek S Wheeler; Stuart L Goldstein
Journal:  Kidney Int       Date:  2013-09-18       Impact factor: 10.612

Review 9.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

10.  [Essential cardiac biomarkers in myocardial infarction and heart failure].

Authors:  M Mueller; E Giannitsis; H A Katus
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.